熱門資訊> 正文
Emergent Bio将支付4000万美元和解集体诉讼
2024-09-13 19:14
- Emergent BioSolutions (NYSE:EBS) announced Friday it has agreed to pay $40M to settle a securities class action litigation pending in the U.S. District Court for the District of Maryland.
- The litigation was initially filed in 2021, representing investors who purchased Emergent’s (EBS) common stock between March 10, 2020, and November 4, 2021.
- The Gaithersburg, Maryland-based biotech was battling lawsuits filed by multiple plaintiffs over claims that the company and some of its current and former senior officers made false and misleading statements about its contract manufacturing capabilities related to COVID-19 shots.
- Emergent (EBS) added that the proposed settlement does not include an admission of wrongdoing by the company or its current or former employees or executives. The settlement is subject to court approval.
More on Emergent Biosolutions
- Mpox Stocks Have Popped, But Pickings Are Slim For The Discerning Investor
- Emergent BioSolutions: Speculative Buy Amid Potential Monkeypox Vaccine Approval
- Emergent BioSolutions Inc. (EBS) Q2 2024 Earnings Call Transcript
- Morocco reports first mpox case amid ongoing global outbreak
- Singapore announces quarantine measures for close contacts of mpox infected patients
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
